Connect Biopharma (CNTB) Competitors $1.72 -0.14 (-7.53%) Closing price 04:00 PM EasternExtended Trading$1.68 -0.03 (-2.03%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. NGNE, CADL, TNXP, IVA, PVLA, LFCR, ABEO, ALDX, CRVS, and DBVTShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Neurogene (NGNE), Candel Therapeutics (CADL), Tonix Pharmaceuticals (TNXP), Inventiva (IVA), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), Corvus Pharmaceuticals (CRVS), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Its Competitors Neurogene Candel Therapeutics Tonix Pharmaceuticals Inventiva Palvella Therapeutics Lifecore Biomedical Abeona Therapeutics Aldeyra Therapeutics Corvus Pharmaceuticals DBV Technologies Neurogene (NASDAQ:NGNE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment. Which has preferable earnings & valuation, NGNE or CNTB? Connect Biopharma has higher revenue and earnings than Neurogene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K342.55-$75.14M-$4.35-5.14Connect Biopharma$26.03M3.67-$15.63MN/AN/A Do analysts prefer NGNE or CNTB? Neurogene currently has a consensus target price of $46.17, indicating a potential upside of 106.65%. Connect Biopharma has a consensus target price of $7.00, indicating a potential upside of 306.98%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NGNE or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -36.16% -32.51% Connect Biopharma N/A N/A N/A Does the media prefer NGNE or CNTB? In the previous week, Connect Biopharma had 5 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Connect Biopharma and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Connect Biopharma's score of 0.43 indicating that Neurogene is being referred to more favorably in the media. Company Overall Sentiment Neurogene Very Positive Connect Biopharma Neutral Do institutionals and insiders believe in NGNE or CNTB? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 11.6% of Neurogene shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, NGNE or CNTB? Neurogene has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500. SummaryConnect Biopharma beats Neurogene on 9 of the 13 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.34M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales3.67303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book1.037.678.125.65Net Income-$15.63M-$55.28M$3.25B$257.91M7 Day Performance13.16%2.50%0.97%2.09%1 Month Performance71.98%11.70%7.36%11.13%1 Year Performance34.38%4.89%31.31%18.40% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma2.6238 of 5 stars$1.72-7.5%$7.00+307.0%+44.2%$103.34M$26.03M0.00110News CoverageHigh Trading VolumeNGNENeurogene3.445 of 5 stars$22.38+4.4%$46.17+106.3%-49.0%$319.11M$925K-5.1490CADLCandel Therapeutics2.518 of 5 stars$6.37+9.6%$22.00+245.5%+5.3%$319.06MN/A-4.7560Positive NewsTNXPTonix Pharmaceuticals2.6032 of 5 stars$42.75+4.6%$585.00+1,268.3%-20.8%$314.54M$10.04M-0.0250Gap UpIVAInventiva3.0874 of 5 stars$3.21-4.3%$10.40+224.5%+30.6%$306.59M$9.95M0.00100PVLAPalvella Therapeutics2.9642 of 5 stars$27.42+3.6%$46.29+68.8%N/A$303.16MN/A-2.27N/APositive NewsLFCRLifecore Biomedical1.0039 of 5 stars$8.17-1.6%$8.00-2.0%+38.1%$302.86M$130.31M-5.64690News CoverageABEOAbeona Therapeutics3.8465 of 5 stars$5.90+2.8%$19.25+226.3%+22.3%$301.79M$3.50M-4.6490ALDXAldeyra Therapeutics2.399 of 5 stars$5.01+7.8%$9.50+89.5%+23.6%$296.79MN/A-5.1110News CoveragePositive NewsCRVSCorvus Pharmaceuticals2.8841 of 5 stars$4.32+4.4%$15.00+247.1%+95.9%$294.63MN/A-4.4130Positive NewsDBVTDBV Technologies4.0198 of 5 stars$10.73-0.7%$14.75+37.5%+142.8%$293.76M$4.15M-2.1880Positive News Related Companies and Tools Related Companies NGNE Competitors CADL Competitors TNXP Competitors IVA Competitors PVLA Competitors LFCR Competitors ABEO Competitors ALDX Competitors CRVS Competitors DBVT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
